ALT Altimmune, Inc. - Fundamental Analysis
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
No reliable valuation metrics exist due to negative earnings; stock trades at a massive premium to sales, likely reflecting speculative growth expectations.
- Low debt/equity ratio (0.16)
- High current and quick ratios (18.55, 18.35)
- Price/Sales of 10,690.50 is extreme
- No Graham Number or intrinsic value available
- No P/E or PEG for valuation
- Negative earnings and cash flow
Future potential is high due to explosive revenue growth and positive earnings surprises, but execution risk is extreme without profitability.
- 420% YoY revenue growth
- Recent earnings surprises above estimates (avg +8.52%)
- Strong analyst target price ($17.22)
- High analyst coverage (9 analysts)
- Positive momentum in recent quarters
- No free cash flow or operating cash flow
- Negative earnings growth (Q/Q -28.6%)
- No clear path to profitability
- High burn rate implied by losses
- No guidance or forward metrics
Past performance shows erratic earnings with periods of extreme underperformance, despite recent improvement in surprise rates.
- Consistent earnings beat in 2025 and 2026 (2/4 in last 4 quarters)
- Improving earnings trend from -0.81 in 2021 to -0.27 in 2026
- Positive surprises in 2023–2025 (e.g., +30.9%, +28.4%)
- Historical losses are massive (e.g., -107.7% surprise in 2021)
- Negative earnings in 2020 and 2021 were severe
- No consistent profitability over 25 quarters
- Earnings volatility is extreme
- Most recent Q/Q EPS growth is -28.6%
Despite strong liquidity, the company's financial health is dire due to persistent losses and poor operational efficiency, as confirmed by the Piotroski F-Score.
- Low debt/equity (0.16)
- High current and quick ratios (18.55, 18.35)
- Piotroski F-Score of 1/9 (extremely weak)
- Negative ROE, ROA, and operating margin
- No Altman Z-Score available, but financial distress is evident
- Negative earnings and cash flow
- No signs of financial stability
ALT is a growth-stage biotech with no dividend policy; this is expected but reflects lack of maturity or profitability.
- No dividend yield or payout
- Payout ratio is 0.00%
- No history of dividend payments
- Company is not a dividend payer
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ALT and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ALT
Altimmune, Inc.
Primary
|
-80.3% | -68.4% | -32.7% | -3.9% | -24.4% | -1.1% |
|
ANGO
AngioDynamics, Inc.
Peer
|
-53.3% | -14.0% | +16.2% | -0.5% | -6.8% | -2.1% |
|
ADCT
ADC Therapeutics SA
Peer
|
-89.4% | -22.9% | +105.1% | +10.1% | +2.3% | -0.3% |
|
ACRS
Aclaris Therapeutics, Inc.
Peer
|
-85.2% | -56.5% | +126.9% | +81.5% | +4.4% | +15.7% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ALT
Altimmune, Inc.
|
BEARISH | $438.31M | - | -50.6% | -% | $3.5 | |
|
ANGO
AngioDynamics, Inc.
|
BEARISH | $436.9M | - | -15.3% | -9.0% | $10.6 | |
|
ADCT
ADC Therapeutics SA
|
NEUTRAL | $447.2M | - | -% | -222.0% | $3.61 | |
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $428.65M | - | -50.2% | -% | $3.54 | |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | WEAVER GREGORY L | Chief Financial Officer | Purchase | 5,000 | $17,700 |
| 2026-03-06 | DURSO JEROME BENEDICT | Chief Executive Officer | Purchase | 20,000 | $70,790 |
| 2026-02-02 | ROBERTS M SCOT | Officer | Stock Award | 17,050 | - |
| 2026-01-30 | JORDT RAYMOND M | Officer | Stock Award | 4,571 | $25,598 |
| 2026-01-30 | ROBERTS M SCOT | Officer | Stock Award | 5,567 | $31,175 |
| 2026-01-30 | GARG VIPIN K. | Director | Stock Award | 6,926 | $38,786 |
| 2026-01-30 | GARG VIPIN K. | Director | Stock Award | 26,775 | - |
| 2026-01-27 | GARG VIPIN K. | Director | Stock Award | 41,200 | - |
| 2026-01-27 | JORDT RAYMOND M | Officer | Stock Award | 15,850 | - |
| 2026-01-23 | ROBERTS M SCOT | Officer | Stock Award | 14,600 | - |
| 2026-01-23 | GARG VIPIN K. | Director | Stock Award | 42,050 | - |
| 2026-01-23 | JORDT RAYMOND M | Officer | Stock Award | 14,600 | - |
| 2026-01-08 | PISANO WAYNE | Director | Purchase | 5,000 | $20,410 |
| 2026-01-05 | SOHN CATHERINE A | Director | Purchase | 500 | $1,755 |
| 2025-12-31 | JORDT RAYMOND M | Officer | Stock Award | 9,375 | - |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning ALT from our newsroom.